Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may improve disease-specific outcomes for inflammatory bowel disease (IBD).
- Tirzepatide, targeting both GLP-1 and another receptor, may provide additional benefits for IBD patients.
- A comparison was made between clinical and safety outcomes of tirzepatide and GLP-1RAs in IBD treatment.
- Evidence indicates that these treatments could be associated with improved management of IBD.
Simplified